A Randomized Phase 1-2 Study of PLM60 in Patients With Peripheral T-Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Conjupro Biotherapeutics
- 06 Jun 2019 Planned End Date changed from 31 Jul 2022 to 1 Jan 2025.
- 06 Jun 2019 Planned primary completion date changed from 30 Jun 2022 to 1 Jan 2024.
- 06 Jun 2019 Status changed from not yet recruiting to suspended.